Soldiering On – The False Claims Act Cases Continue to Significantly Impact Life Science Companies in FY 2017
Gwen Ball, Staff Writer, Life Science Compliance Update
For FY 2017, the Federal False Claim Act continued to be a potent weapon for combating health care fraud by life sciences companies. However, while overall the settlements appeared to hold steady, there were more defendants and smaller settlements. This article explores the FY 2017 data for what it may reveal about the future of FCA cases against life sciences companies.